Literature DB >> 9415028

Apoptosis with FasL+ cell infiltration in the periphery and thymus of corrected autoimmune mice.

T Kobata1, K Takasaki, H Asahara, N M Hong, K Masuko-Hongo, T Kato, S Hirose, T Shirai, N Kayagaki, H Yagita, K Okumura, K Nishioka.   

Abstract

Fas (CD95) ligand (L) is a death factor that binds to its receptor, Fas, and induces apoptotic cell death, a crucial process in immunological tolerance. gld (generalized lymphoproliferative disorder) mice, which have a point mutation in the FasL gene, develop spontaneous systemic autoimmune syndromes characterized by hypergammaglobulinaemia and lymphoid hyperplasia owing to accumulation of abnormal B220+ CD3+ cells. Transplantation of wild-type (wt) bone marrow cells into old gld mice on the same strain background results in normalization of autoimmune syndromes. We characterized the cellular mechanisms (functionally and histologically) of the above phenomena in gld mice after bone marrow transplantation (BMT) to determine the role of apoptosis via Fas/FasL interactions in inducing and maintaining self-tolerance in vivo. Activated splenocytes from wt and BMT (wt to gld) mice showed significant cytotoxic activity against Fas transfectant cells while those from BMT (gld to gld) mice did not. Cells in the thymus, spleen and lymph nodes of gld mice uniformly upregulated Fas expression and were sensitive to Fas-mediated apoptosis compared with those in wt mice. Cells sensitive to Fas-mediated apoptosis in gld mice resided not only among abnormal B220+ CD3+ cells but also among conventional lymphocytes. More importantly, histological analysis revealed that cells in the spleen, lymph nodes and thymus frequently underwent apoptosis with infiltration of FasL+ cells in BMT (wt to gld) mice compared with BMT (gld to gld) mice. Our results indicated that apoptosis via Fas/FasL interactions can directly eliminate pathogenic cells responsible for autoimmunity in the periphery and possibly in the thymus in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415028      PMCID: PMC1364060          DOI: 10.1046/j.1365-2567.1997.00347.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Co-infusion of normal bone marrow partially corrects the gld T-cell defect. Evidence for an intrinsic and extrinsic role for Fas ligand.

Authors:  E S Sobel; V N Kakkanaiah; M Kakkanaiah; P L Cohen; R A Eisenberg
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

2.  In vivo depletion of Thy-1-positive cells originating from normal bone marrow abrogates the suppression of gld disease in normal-gld mixed bone marrow chimeras.

Authors:  G C MacDonald; V N Kakkanaiah; E S Sobel; P L Cohen; R A Eisenberg
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

3.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

4.  Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse.

Authors:  T Zhou; H Bluethmann; J Eldridge; K Berry; J D Mountz
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

5.  Chronic treatment of C3H-lpr/lpr and C3H-gld/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production.

Authors:  T Giese; W F Davidson
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

6.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

7.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

8.  Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome.

Authors:  J L Chu; P Ramos; A Rosendorff; J Nikolić-Zugić; E Lacy; A Matsuzawa; K B Elkon
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

9.  Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody.

Authors:  J Ogasawara; T Suda; S Nagata
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

10.  Cytotoxicity of fresh NK1.1+ T cell receptor alpha/beta+ thymocytes against a CD4+8+ thymocyte population associated with intact Fas antigen expression on the target.

Authors:  H Arase; N Arase; Y Kobayashi; Y Nishimura; S Yonehara; K Onoé
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  2 in total

1.  Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice.

Authors:  Jerold E Rehg; John P Sundberg
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

2.  Prenatal exposure of mice to diethylstilbestrol disrupts T-cell differentiation by regulating Fas/Fas ligand expression through estrogen receptor element and nuclear factor-κB motifs.

Authors:  Narendra P Singh; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2012-08-10       Impact factor: 4.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.